Related Experiment Videos
[Interferon for hemangiomas of infancy]
Harefuah
|April 15, 1994
Summary
Interferon alpha-2a effectively treats large, symptomatic infantile hemangiomas, resolving symptoms and reducing lesion size without significant side effects. This offers a promising new therapeutic option for infants with severe cases.
Area of Science:
- Pediatric Oncology
- Dermatology
- Pharmacology
Background:
- Infantile hemangiomas are common vascular tumors, typically benign but sometimes causing severe complications.
- Current treatments like corticosteroids have limitations, including rebound effects.
Observation:
- A 3.5-month-old infant presented with a large, symptomatic hemangioma.
- The infant was treated with interferon alpha-2a (3 million units/m2/day) for six months.
Findings:
- Treatment resulted in complete resolution of symptoms.
- The hemangioma lesion size was reduced by 50%.
- No significant adverse effects were observed during treatment.
Implications:
- Interferon alpha-2a demonstrates safety and efficacy for treating severe infantile hemangiomas.
- This therapy should be considered for infants with large, symptomatic hemangiomas unresponsive to other treatments.